 |
|
Neurodevelopmental and Growth Impairment Among Extremely Low-Birth-Weight Infants With Neonatal Infection
Barbara J. Stoll, MD;
Nellie I. Hansen, MPH;
Ira Adams-Chapman, MD;
Avroy A. Fanaroff, MD;
Susan R. Hintz, MD;
Betty Vohr, MD;
Rosemary D. Higgins, MD; for the National Institute of Child Health and Human Development Neonatal Research Network
JAMA. 2004;292:2357-2365.
ABSTRACT
| |
Context Neonatal infections are frequent complications of extremely low-birth-weight (ELBW) infants receiving intensive care.
Objective To determine if neonatal infections in ELBW infants are associated with increased risks of adverse neurodevelopmental and growth sequelae in early childhood.
Design, Setting, and Participants Infants weighing 401 to 1000 g at birth (born in 1993-2001) were enrolled in a prospectively collected very low-birth-weight registry at academic medical centers participating in the National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental and growth outcomes were assessed at a comprehensive follow-up visit at 18 to 22 months of corrected gestational age and compared by infection group. Eighty percent of survivors completed the follow-up visit and 6093 infants were studied. Registry data were used to classify infants by type of infection: uninfected (n = 2161), clinical infection alone (n = 1538), sepsis (n = 1922), sepsis and necrotizing enterocolitis (n = 279), or meningitis with or without sepsis (n = 193).
Main Outcome Measures Cognitive and neuromotor development, neurologic status, vision and hearing, and growth (weight, length, and head circumference) were assessed at follow-up.
Results The majority of ELBW survivors (65%) had at least 1 infection during their hospitalization after birth. Compared with uninfected infants, those in each of the 4 infection groups were significantly more likely to have adverse neurodevelopmental outcomes at follow-up, including cerebral palsy (range of significant odds ratios [ORs], 1.4-1.7), low Bayley Scales of Infant Development II scores on the mental development index (ORs, 1.3-1.6) and psychomotor development index (ORs, 1.5-2.4), and vision impairment (ORs, 1.3-2.2). Infection in the neonatal period was also associated with impaired head growth, a known predictor of poor neurodevelopmental outcome.
Conclusions This large cohort study suggests that neonatal infections among ELBW infants are associated with poor neurodevelopmental and growth outcomes in early childhood. Additional studies are needed to elucidate the pathogenesis of brain injury in infants with infection so that novel interventions to improve these outcomes can be explored.
INTRODUCTION
The increased survival of extremely low-birth-weight (ELBW) infants (ie, weighing 401-1000 g at birth) has heightened awareness of the importance of assessing and improving long-term outcomes associated with prematurity.1-4 It is estimated that as many as 15% of the most immature infants develop cerebral palsy (CP) and approximately half develop cognitive and behavioral deficits.1-5 Cerebral white matter damage, identified by cranial ultrasound or magnetic resonance imaging, is a powerful predictor of CP in low-birth-weight preterm infants.5-6 Investigators have reported associations among antenatal infection, a fetal inflammatory response, vasculitis, white matter damage, and long-term disability.7-10
Infections are a frequent complication among ELBW preterm infants11-12 and are associated with short-term sequelae and an increased risk of death. This study was undertaken to determine if neonatal infections are associated with adverse neurodevelopmental and growth sequelae in early childhood.
METHODS
Study Population
The National Institute of Child Health and Human Development (NICHD) Neonatal Research Network maintains a registry of very low-birth-weight (VLBW) infants (weighing 401-1500 g at birth).13 Trained personnel collect maternal and delivery data soon after birth and infant data for 120 days (with end points of discharge or death). Surviving infants who weighed 1000 g or less at birth are asked to return for a comprehensive visit at 18 to 22 months of corrected gestational age. Outcomes of ELBW infants born between January 1, 1993, and August 31, 2001, who participated in the VLBW registry and follow-up studies were assessed. Infants with major congenital malformations/syndromes and those with ventricular shunts were excluded because of possible adverse effects on outcome. The institutional review boards at each center approved participation in the registry and the follow-up studies. Written informed consent was obtained from parents or legal guardians for follow-up.
Clinical Methods
Maternal and neonatal data included maternal age, antenatal antibiotic and steroid use, timing of rupture of membranes, mode of delivery, birth weight, gestational age, sex, race/ethnicity, postnatal surfactant, antibiotic, and steroid use, and diagnoses of respiratory distress syndrome (RDS), patent ductus arteriosus (PDA), intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), and infection. Maternal race, determined by chart abstraction, was recorded for the infant. Bronchopulmonary dysplasia was defined by use of supplemental oxygen at 36 weeks of postconceptional age (PCA), NEC was classified according to the system of Bell et al,14 and IVH was classified according to the method of Papile et al.15
Growth charts developed by Alexander et al16 were used to classify infants as small for gestational age at birth, defined by a birth weight lower than the 10th percentile for sex and gestational age. Infants were classified at less than the 10th percentile for head circumference at birth using intrauterine growth data reported by Thomas et al.17 These data were further used to classify study infants at less than the 10th percentile for weight and head circumference at 36 weeks of PCA, compared with infants born at 36 weeks of gestation (data used to create curves in article by Thomas et al,17 Reese Clark, Pediatrix Medical Group, written communication, April 1, 2004). When the 36-week PCA measurements were unavailable, the closest measurement between 34 and 38 weeks was used.
Early-onset ( 72 hours of birth) and late-onset (>72 hours) sepsis (EOS and LOS, respectively) were defined by a positive blood culture and antibiotic therapy for 5 or more days. Meningitis was defined by a positive cerebrospinal fluid culture and antibiotic therapy for 5 or more days. Cultures positive for organisms generally considered to be contaminants (ie, corynebacterium, propionibacterium, diphtheroids) were excluded. Infants were classified by type of infection as follows: uninfected (no EOS, LOS, late-onset culture-negative clinical infection, NEC, or meningitis); clinical infection alone (late-onset cultures negative but antibiotic treatment for  5 days); sepsis alone (EOS/LOS); sepsis and NEC (not always concurrent); or meningitis with or without sepsis. Patients with NEC were included because of the strong association of NEC with infection.18
The follow-up visit included an interview with the infant’s mother or other primary caregiver, an assessment of cognitive and neuromotor development using the Bayley Scales of Infant Development II19 and a neurologic examination (both by certified examiners), ascertainment of vision and hearing by caregiver report, and measurement of weight, length, and head circumference. Bayley scale scores provide mental (MDI) and psychomotor (PDI) developmental indexes. The mean score is 100; a score of less than 70 (>2 SDs below the mean) indicates significant delay. Infants judged to be so severely delayed that they were untestable were assigned MDI and PDI scores of 49. Cerebral palsy was defined as a nonprogressive disorder characterized by abnormal tone in at least 1 extremity and abnormal control of movement and posture. Vision impairment was defined as blindness in one or both eyes or need for corrective lenses. Hearing impairment was defined as hearing aids in one or both ears. A composite outcome, neurodevelopmental impairment, was defined as MDI score of less than 70, PDI score of less than 70, CP, bilateral blindness, or bilateral hearing impairment. Centers for Disease Control and Prevention growth charts were used to determine growth status at follow-up (weight, length, and head circumference <10th percentile for sex and age).20
In a secondary analysis, infants in the sepsis alone group were classified by the following pathogen types: coagulase-negative staphylococci; other gram-positive; gram-negative; fungal; and combinations (>1 episode of infection, each with a different pathogen, or polymicrobial bacteremia); and compared with uninfected infants.
Statistical Analyses
Statistical significance for unadjusted comparisons was determined by  2 tests. Logistic regression models, adjusting for potential confounding variables, were used to compare infected and uninfected infants. Weight and head circumference at 36 weeks of PCA and outcomes evaluated at follow-up (MDI <70; PDI <70; CP; vision impairment; hearing impairment; neurodevelopmental impairment; and weight, length, and head circumference <10th percentile) were compared. Models included infection group (or pathogen type), study center, gestational age, birth weight, sex, race/ethnicity, rupture of membranes more than 24 hours before delivery, mode of delivery, multiple birth, antenatal antibiotic and steroid use, postnatal surfactant and steroid use, RDS, BPD, PDA, IVH grade 3 or 4, PVL, and maternal age at the time of delivery. Covariates were entered as categorical variables except maternal age at the time of delivery. Models fitted to the follow-up outcomes also included caregiver’s education at the follow-up visit (high school degree or not). Because not all infants were evaluated for PVL, a 3-level variable (yes, no, or missing) was included in all models. Each model was also run adding head circumference of less than the 10th percentile at 36 weeks of PCA to explore whether head circumference was a mediating variable between infection and outcome. Head circumference was entered as a 3-level variable because of missing values. Odds ratios (ORs) and 95% confidence intervals (CIs) are reported. Wald 2 tests were used to determine significance for comparisons between infection or pathogen groups, with P<.05 considered statistically significant. Analyses were performed using SAS statistical software.21
RESULTS
Between January 1, 1993, and August 31, 2001, 13 013 ELBW infants were entered into the network’s prospective registry; 4160 infants died before discharge and 226 died after discharge. Infants with major congenital malformations (n = 337), those with ventricular shunts (n = 159), and those with positive blood cultures but receiving antibiotic therapy for less than 5 days (and therefore considered probable contaminants; n = 239) were excluded from this analysis. Thus, 7892 infants were eligible for follow-up and 6314 (80%) completed the follow-up visit.
Of the 6314 infants who completed follow-up, 6093 were analyzed and categorized as follows: 2161 (35%) were uninfected; 1538 (25%) had clinical infection alone; 1922 (32%) had sepsis alone (EOS, n = 52; LOS, n = 1844; both, n = 26); 279 (5%) had sepsis/NEC (EOS, n = 5; LOS, n = 266; both, n = 8); and 193 (3%) had meningitis (with sepsis, n = 136 [EOS, n = 2; LOS, n = 128; both, n = 6], or without sepsis, n = 57). Thirteen infants could not be classified because of missing information and 208 infants with various combinations of sepsis, meningitis, and NEC were excluded because of small numbers.
Infection status of the infants who died (and were therefore unavailable for follow-up) and of all survivors was assessed. Because limited information was available for those who died in the first 12 hours after delivery, we evaluated infants who died more than 12 hours after delivery. Infection was included in the coded cause of death for 27% of these infants. Because most deaths among ELBW infants occurred in the first week of life, many did not survive long enough to develop LOS. Thus, infants who died more than 12 hours after delivery were more likely than survivors to be uninfected (46% vs 35%) and less likely to have clinical infection (11% vs 24%) or sepsis alone (23% vs 30%). Overall, they were more likely to have had NEC with or without sepsis (17% vs 7%). Approximately 4% in each group had meningitis. Compared with the survivors seen at the follow-up visit, infants who were alive but did not complete their follow-up visit were more likely to be uninfected (39% vs 35%), and the percentages in each infection group were 1% to 2% lower than for study infants (P = .001).
Maternal and neonatal characteristics of the study population are presented in Table 1. Compared with the uninfected infants, those with infection were more immature, had lower birth weights, were more frequently male, and had several complications that have been linked to adverse long-term sequelae, including severe IVH, PVL, BPD, postnatal steroid use, and poor growth (Table 2). After adjusting for study center and maternal and neonatal variables, infants in each infection group were significantly more likely than the uninfected infants to have a head circumference of less than the 10th percentile at 36 weeks of PCA (adjusted OR vs uninfected for clinical infection alone, 1.8; 95% CI, 1.5-2.2; for sepsis alone, 2.5; 95% CI, 2.1-3.0; for sepsis/NEC, 4.0; 95% CI, 2.9-5.6; and for meningitis, 3.0; 95% CI, 2.1-4.4) and to be at less than the 10th percentile for weight at 36 weeks of PCA (adjusted OR vs uninfected for clinical infection alone, 1.8; 95% CI, 1.5-2.2; for sepsis alone, 2.2; 95% CI, 1.9-2.7; for sepsis/NEC, 3.1; 95% CI, 2.1-4.5; and for meningitis, 2.2; 95% CI, 1.4-3.3).
|
|
|
|
Table 1. Maternal and Neonatal Characteristics of Study Population by Infection Group vs Uninfected Infants
|
|
|
|
|
|
|
Table 2. Clinical Characteristics of Study Population by Infection Group vs Uninfected Infants
|
|
|
Follow-up Outcomes by Infection Group
Overall, 41% of children assessed at 18 to 22 months of corrected gestational age had at least 1 adverse neurodevelopmental outcome (data not shown). In unadjusted comparisons, children with infection had significant increases in most adverse outcomes (Table 3). In general, infants without infection were least likely to have adverse outcomes, while those with sepsis/NEC were most likely. Overall 62% of children in the cohort had weight, length, or head circumferences that were less than the 10th percentile at follow-up (data not shown). By univariate analyses, infected children were more likely than those who were uninfected to have growth failure (<10th percentile) at follow-up (Table 4).
|
|
|
|
Table 3. Neurodevelopmental Outcomes From Univariate Analyses by Infection Group vs Uninfected Infants
|
|
|
|
|
|
|
Table 4. Growth Outcomes From Univariate Analyses by Infection Group vs Uninfected Infants
|
|
|
After adjusting for study center and maternal and neonatal variables, statistically significant differences for all neurodevelopmental outcomes except hearing impairment were found between children in most infection groups and the uninfected group (Table 5). Only children who had sepsis or sepsis/NEC were at an increased risk of hearing impairment. When head circumference that was less than the 10th percentile at 36 weeks was added to each model, differences between infected and uninfected groups were reduced somewhat; however, a significant association remained for all outcomes except CP (without head circumference, P = .009; with head circumference, P = .07).
|
|
|
|
Table 5. Neurodevelopmental and Growth Outcomes Assessed by ORs for Infants With Infection vs Uninfected Infants by Logistic Regression Analysis*
|
|
|
Children in each infection group were significantly more likely to have head circumferences that were less than the 10th percentile at follow-up than uninfected children (Table 5). In contrast, only children in the sepsis/NEC and the meningitis groups were more likely than those who were uninfected to be at less than the 10th percentile for length and only those in the sepsis/NEC group were more likely to be at less than the 10th percentile for weight.
Follow-up Outcomes by Pathogen Group
Children in the sepsis alone group were evaluated by infecting organisms (coagulase-negative staphylococci, n = 925; other gram-positive, n = 278; gram-negative, n = 197; fungal, n = 105; and combinations, n = 399) and compared with uninfected children. Eighteen children with sepsis were excluded because pathogen information was unavailable. The majority of children had 1 episode of sepsis. By definition, patients in the combination group had more than 1 episode of sepsis, each with a different organism, or had 1 episode of polymicrobial bacteremia. Unadjusted comparisons between pathogen group and outcomes are shown in Table 6. All adverse neurodevelopmental outcomes except hearing impairment were higher among infected children regardless of pathogen type. Hearing impairment was significantly higher for those with gram-negative or fungal infections and those in the combination group. Compared with uninfected children, those in each pathogen group were more likely to have head circumferences that were less than the 10th percentile at follow-up. Fewer differences were found between children in the pathogen groups and uninfected children for weight and length.
|
|
|
|
Table 6. Neurodevelopmental and Growth Outcomes From Univariate Analysis for Pathogen Groups Among Infants With Sepsis Only vs Uninfected Infants
|
|
|
After adjusting for study center and maternal and neonatal variables, statistically significant differences were found for children in some pathogen groups compared with those not infected (Table 7). However, for all outcomes except hearing impairment, we detected no differences in risk by type of infecting pathogen. Compared with infants with coagulase-negative staphylococcus infection, those with gram-negative infections (OR, 2.5; 95% CI, 1.0-6.3) and those in the combination group (OR, 2.7; 95% CI, 1.3-5.5) were significantly more likely to have hearing impairment.
|
|
|
|
Table 7. Neurodevelopmental and Growth Outcomes Assessed by ORs for Pathogen Groups Among Infants With Sepsis Only vs Uninfected Infants by Logistic Regression Analysis*
|
|
|
COMMENT
Infection is an important problem among VLBW preterm infants. Previous studies from the NICHD Neonatal Research Network have demonstrated that as many as 25% of these infants have 1 or more positive blood cultures and about 5% have a positive cerebrospinal fluid culture over the course of their neonatal hospitalization.11-12,22 Rates of infection increase with decreasing birth weight and gestational age. Moreover, postnatal infection is associated with an increased risk of neonatal complications, prolonged hospitalization, and death.11-12
This study was undertaken to determine if neonatal infections are associated with adverse sequelae in early childhood. Although few studies have directly addressed infection and outcome, neonatal sepsis was first linked to cerebral white matter damage in term infants more than 30 years ago.23 Follow-up studies of preterm infants have suggested an association between sepsis and cerebral white matter damage and CP.24-27 A recent report from the United Kingdom noted a 4-fold increase in CP among VLBW infants with a history of neonatal sepsis compared with infants with no history of neonatal infection.27
To our knowledge, this is the largest study to date to evaluate the impact of neonatal infection on adverse outcomes in early childhood. More than 6000 ELBW infants were classified by infection during initial hospitalization and were seen in follow-up at 18 to 22 months of corrected age. Culture-confirmed neonatal infection increased the rate of several adverse neurodevelopmental outcomes that contribute to long-term disability, including significantly delayed mental and psychomotor Bayley Scales of Infant Development II scores, vision and hearing impairment, and CP. Of interest, clinical infection alone was also associated with increased risk for adverse outcomes and infants with sepsis/NEC were at highest risk. Although we suspected that infants with gram-negative or fungal infections might have worse neurodevelopmental outcomes than those infected with other pathogens, the type of infecting pathogen had little effect on outcome among survivors. This may be explained in part by the high mortality rate among those infected with gram-negative and fungal organisms.11-12
Intrauterine infection, as evidenced by clinical and/or histologic chorioamnionitis, is associated with cerebral white matter injury and subsequent neurodevelopmental impairment.28-32 A key role for an inflammatory response by the fetus as well as the mother in the pathogenesis of brain injury has been postulated.33-35 Proinflammatory cytokines in amniotic fluid and in fetal or neonatal blood appear to increase the risk for neonatal brain injury and adverse long-term outcome.
Studies to elucidate the pathophysiology of brain injury in infants with neonatal infection are warranted. Infecting organisms and/or their microbial products can stimulate the production of proinflammatory cytokines. Experimental data indicate that inflammatory cytokines may be neurotoxic in vitro and in vivo and may increase the permeability of the preterm blood-brain barrier.36-40 Although it appears that the inflammatory cytokine response precedes and contributes to brain injury, a cytokine response may also be the result and/or marker of damaged white matter. Efforts to reduce the inflammatory responses of the neonate with infection might reduce the risk of brain injury associated with infection, but must be approached with caution.41-42
Neonates with infection are also at risk for circulatory and/or respiratory insufficiency with decreased systemic blood pressure, hypoxemia, and pathologic alterations in cerebral blood flow. A maturation-dependent impairment in regulation of cerebral blood flow in ELBW43 infants increases the risk of ischemic injury. The long-term impact of cerebral ischemia-reperfusion precipitated by sepsis-related cardiovascular instability is unclear. Volpe44-46 and others have shown that oligodendroglial precursor cells, the major cellular target in the pathogenesis of white matter injury/PVL, are particularly vulnerable to free radicals that are generated in response to ischemia-reperfusion. The role of infection and cytokines in the pathogenesis of PVL might be related to effects on cerebral hemodynamics, to the generation of reactive oxygen species/free radicals, or to direct toxic effects on vulnerable oligodendroglial precursors.44, 46
Hearing impairment was more frequent among children who survived neonatal sepsis or sepsis/NEC, especially if they were infected with gram-negative agents or had polymicrobial bacteremia or multiple infections. This finding likely reflects that aminoglycosides are often used to treat these infections. At first glance, it is curious that infants with meningitis were not more likely to have hearing impairment. However, because gram-positive organisms have been more commonly associated with neonatal meningitis among network infants,22 prolonged therapy with aminoglycosides may be less likely. Aminoglycoside ototoxicity is a known complication of prolonged high drug levels; at lower levels there appears to be genetic susceptibility to ototoxicity.47-48 It is unclear whether infants with hearing loss who received aminoglycosides in the neonatal period should be screened for the presence of the mitochondrial mutations known to increase risk.
Many VLBW infants fail to achieve their ultimate growth potential as a result of intrauterine and postnatal growth failure.49 Impaired head growth and subnormal head size are associated with poor cognitive function and academic achievement at 8 years of age,50 suggesting a link between postnatal growth and neurodevelopmental potential. Recently, the NICHD Neonatal Research Network reported that while 16% of ELBW infants were small for gestational age at birth, by 36 weeks of PCA, 89% had growth failure.51 Furthermore, by 18 to 22 months of corrected age, 40% still were at less than the 10th percentile for weight, length, and head circumference.52 Our study demonstrates that infection affects weight and head circumference at both 36 weeks of PCA and 18 to 22 months of corrected gestational age. Of greatest concern was our finding that infants with neonatal infections were significantly more likely to have poor head growth. The long-term impact of impaired growth during and following neonatal infections deserves further study.
The major limitation of our study is that neurodevelopmental and growth status were assessed by a single follow-up visit. Outcomes may change as children get older; ie, some may improve, some remain unchanged, or some may worsen. Although patients who returned for follow-up had slightly higher rates of infection, it is unlikely that these differences between survivors who did and did not return for follow-up were clinically significant or affected the study’s robust findings. It also is difficult to speculate on the possible bias introduced by infants who died before follow-up. Because we studied the most immature ELBW infants, many of whom had very complicated neonatal courses, we do not know whether our findings are applicable to larger preterm or term infants.
In summary, this large cohort study demonstrates an association between neonatal infection in ELBW infants and increased risk of poor neurodevelopmental and growth outcomes. Possible interventions to reduce brain injury associated with infection might include earlier diagnosis and improved therapies, including efforts to stabilize blood pressure and maintain adequate oxygenation, reduction of systemic inflammation and generation of proinflammatory cytokines, and pharmacologic interventions to reduce the impact of reactive oxygen species on vulnerable oligodendroglial precursors. Ultimately, efforts to reduce the high rates of infection in ELBW infants are the most important interventions.
AUTHOR INFORMATION
Corresponding Author: Barbara J. Stoll, MD, Department of Pediatrics, Emory University School of Medicine, 2015 Uppergate Dr, Atlanta, GA 30322.
Author Contributions: Dr Stoll had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Stoll, Adams-Chapman, Fanaroff.
Acquisition of data: Stoll, Fanaroff, Hintz, Vohr.
Analysis and interpretation of data: Stoll, Hansen, Adams-Chapman, Hintz, Vohr, Higgins.
Drafting of the manuscript: Stoll, Hansen, Fanaroff, Higgins.
Critical revision of the manuscript for important intellectual content: Stoll, Hansen, Adams-Chapman, Hintz, Vohr, Higgins.
Statistical analysis: Hansen.
Obtained funding: Stoll.
Administrative, technical, or material support: Stoll, Higgins.
Study supervision: Stoll, Higgins.
The National Institute of Child Health and Human Development Neonatal Research Network: Brown University: William Oh, MD (principal investigator [PI]), Betty Vohr, MD (follow-up PI), Angelita Hensman, RNC (network coordinator [NC]), Lucy Noel, RNC (follow-up coordinator [FC]); Case Western Reserve University: Avroy A. Fanaroff, MB,BCh (PI), Dee Wilson, MD (follow-up PI), Nancy Newman, RN (NC), Bonnie Siner, RN (FC); Duke University: Ronald N. Goldberg, MD (PI), Ricki Goldstein, MD (follow-up PI), Kathy Auten, RN, BS (NC), Melody Lohmeyer, RN (FC); Emory University: Barbara J. Stoll, MD (PI, follow-up PI), Ellen Hale, RNC, BS (NC, FC); Harvard University: Ann R. Stark, MD (PI, follow-up PI), Kerri Fournier, RN (NC); Indiana University: James A. Lemons, MD (PI), Anna Dusick, MD (follow-up PI), DeeDee Appel, RN (NC), Leslie Richards, RN (FC); Stanford University: David K. Stevenson, MD (PI), Susan Hintz, MD (follow-up PI), Bethany Ball, RN, BS (NC, FC); University of Alabama: Waldemar A. Carlo, MD (PI), Kathy Nelson, MD (follow-up PI), Monica Collins, RN (NC); Vivien Phillips (FC); University of California, San Diego: Neil N. Finer, MD (PI), Yvonne Vaucher, MD (follow-up PI), Chris Henderson, RN (NC), Martha Fuller, RN (FC); University of Cincinnati: Edward F. Donovan, MD (PI), Jean Steichen, MD (follow-up PI), Cathy Grisby, RN (NC), Tari Gratton, RN (FC); University of Miami: Shahnaz Duara, MD (PI), Charles Bauer, MD (follow-up PI), Ruth Everett, RN (NC), Mary Allison, RN (FC); University of New Mexico: Lu-Ann Papile, MD (PI, follow-up PI), Conra Backstrom, RN (NC); University of Rochester: Dale L. Phelps, MD (PI), Gary Myers, MD (follow-up PI), Linda Reubens, RN (NC), Diane Hust, RN (FC); University of Tennessee: Sheldon B. Korones, MD (PI), Kimberly Yolton, PhD (follow-up PI), Tina Hudson, RN (NC); University of Texas, Dallas: Abbot R. Laptook, MD (PI), Roy Heyne, MD (follow-up PI), Susie Madison, RN (NC), Jackie Hickman, RN (FC); University of Texas, Houston: Jon E. Tyson, MD, MPH (PI), Brenda Morris, MD (follow-up PI), Georgia McDavid, RN (NC) Shannon Rossi (FC); Wake Forest University: T. Michael O’Shea, MD (PI), Robert Dillard, MD (follow-up PI), Nancy Peters, RN (NC), Barbara Jackson, RN (FC); Wayne State University: Seetha Shankaran, MD (PI), Yvette Johnson, MD (follow-up PI), Gerry Muran, BSN (NC); Debbie Kennedy, RN (FC); Yale University: Richard A. Ehrenkranz, MD (PI), Linda Mayes, MD (follow-up PI), Pat Gettner, RN (NC), Elaine Romano, MSN (FC); NICHD: Linda L. Wright, MD (PI), Rosemary D. Higgins, MD (PI), Beth B. McClure, MS (NC); Research Triangle Institute: W. Kenneth Poole, PhD (PI, follow-up PI), Betty Hastings, Carolyn Petrie, MS (NCs), Beth B. McClure, MS (FC); steering committee chairman: Alan H. Jobe, MD, PhD.
Funding/Support: This work was supported by grants U10 HD21397, U10 HD34216, U10 HD27853, U10 HD27871, U10 HD21364, U10 HD40461, U10 HD40492, U10 HD21415, U10 HD40689, U10 HD27856, U10 HD27904, U10 HD40498, U10 HD27881, U10 HD40521, U01 HD36790, U10 HD21385, U10 HD34167, U10 HD27880, U10 HD27851, U10 HD21373, and U01 HD19897 from the National Institutes of Health.
Role of the Sponsor: The NICHD provided oversight of the project through a cooperative agreement—a grant wherein the funding federal agency is substantially involved in carrying out the research program and federal scientists collaborate with researchers on a joint research project.
Author Affiliations: Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga (Drs Stoll and Adams-Chapman); Research Triangle Institute, Research Triangle Park, NC (Ms Hansen); Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio (Dr Fanaroff); Division of Neonatology, Stanford University Medical Center, Palo Alto, Calif (Dr Hintz); Department of Pediatrics, Brown University, Providence, RI (Dr Vohr); and the National Institute of Child Health and Human Development, Bethesda, Md (Dr Higgins).
REFERENCES
| |
1. Vohr BR, Wright LL, Dusick AM, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. Pediatrics. 2000;105:1216-1226.
FREE FULL TEXT
2. Hack M, Wilson-Costello D, Friedman H, et al. Neurodevelopment and predictors of outcomes of children with birth weights of less than 1000 g: 1992-1995. Arch Pediatr Adolesc Med. 2000;154:725-731.
FREE FULL TEXT
3. O’Shea TM, Preisser JS, Klinepeter KL, Dillard RG. Trends in mortality and cerebral palsy in a geographically based cohort of very low birth weight neonates born between 1982 to 1994. Pediatrics. 1998;101:642-647.
FREE FULL TEXT
4. Lorenz JM, Wooliever DE, Jetton JR, Paneth N. A quantitative review of mortality and developmental disability in extremely premature newborns. Arch Pediatr Adolesc Med. 1998;152:425-435.
FREE FULL TEXT
5. Pinto-Martin JA, Riolo S, Cnaan A, Holzman C, Susser MW, Paneth N. Cranial ultrasound prediction of disabling and nondisabling cerebral palsy at age two in a low birth weight population. Pediatrics. 1995;95:249-254.
FREE FULL TEXT
6. Perlman JM. White matter injury in the preterm infant: an important determination of abnormal neurodevelopment outcome. Early Hum Dev. 1998;53:99-120.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
7. Dammann O, Kuban KC, Leviton A. Perinatal infection, fetal inflammatory response, white matter damage, and cognitive limitations in children born preterm. Ment Retard Dev Disabil Res Rev. 2002;8:46-50.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
8. Dammann O, Durum S, Leviton A. Do white cells matter in white matter damage? Trends Neurosci. 2001;24:320-324.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
9. O’Shea TM, Klinepeter KL, Meis PJ, Dillard RG. Intrauterine infection and risk of cerebral palsy in very low-birthweight infants. Paediatr Perinat Epidemiol. 1998;12:72-83.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
10. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res. 1997;42:1-8.
WEB OF SCIENCE
| PUBMED
11. Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med. 2002;347:240-247.
FREE FULL TEXT
12. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD neonatal research network. Pediatrics. 2002;110:285-291.
FREE FULL TEXT
13. Hack M, Horbar JD, Malloy MH, Tyson JE, Wright E, Wright L. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Network. Pediatrics. 1991;87:587-597.
FREE FULL TEXT
14. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis: therapeutic decisions based on clinical staging. Ann Surg. 1978;187:1-7.
WEB OF SCIENCE
| PUBMED
15. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92:529-534.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
16. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol. 1996;87:163-168.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
17. Thomas P, Peabody J, Turnier V, Clark RH. A new look at intrauterine growth and the impact of race, altitude, and gender. Pediatrics. 2000;106:e21. Available at: http://pediatrics.org/cgi/content/full/106/2/e21. Accessed August 2000.
18. Willoughby RE, Pickering LK. Necrotizing enterocolitis and infection. Clin Perinatol. 1994;21:307-315.
WEB OF SCIENCE
| PUBMED
19. Bayley N. Bayley Scales of Infant Development II. San Antonio, Tex: Psychological Corp; 1993.
20. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. June 8, 2000(314):1-27. Available at: http://www.cdc.gov/growthcharts. Accessed August 2000.
21. SAS/STAT User’s Guide, Version 8. Cary, NC: SAS Institute Inc; 1999.
22. Stoll BJ, Hansen N, Fanaroff AA, et al. To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants. Pediatrics. 2004;113:1181-1186.
FREE FULL TEXT
23. Leviton A, Gilles FH. An epidemiologic study of perinatal telencephalic leucoencephalopathy in an autopsy population. J Neurol Sci. 1973;18:53-66.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
24. Faix RG, Donn SM. Association of septic shock caused by early-onset group B streptococcal sepsis and periventricular leukomalacia in the preterm infant. Pediatrics. 1985;76:415-419.
FREE FULL TEXT
25. Murphy DJ, Hope PL, Johnson A. Neonatal risk factors for cerebral palsy in very preterm babies: case-control study. BMJ. 1997;314:404-408.
FREE FULL TEXT
26. Msall ME, Buck GM, Rogers BT, et al. Multivariate risks among extremely premature infants. J Perinatol. 1994;14:41-47.
PUBMED
27. Wheater M, Rennie JM. Perinatal infection is an important risk factor for cerebral palsy in very-low-birthweight infants. Dev Med Child Neurol. 2000;42:364-367.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
28. Wu YW, Colford JM. Chorioamnionitis as a risk factor for cerebral palsy. JAMA. 2000;284:1417-1424.
FREE FULL TEXT
29. Yoon BH, Park C-W, Chaiworapongsa T. Intrauterine infection and the development of cerebral palsy. BJOG. 2003;110:124-127.
PUBMED
30. Nelson KB, Willoughby RE. Overview: infection during pregnancy and neurologic outcome in the child. Ment Retard Dev Disabil Res Rev. 2002;8:1-2.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
31. O’Shea TM. Cerebral palsy in very preterm infants: new epidemiological insights. Ment Retard Dev Disabil Res Rev. 2002;8:135-145.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
32. Schendel DE, Schuchat A, Thorsen P. Public health issues related to infection in pregnancy and cerebral palsy. Ment Retard Dev Disabil Res Rev. 2002;8:39-45.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
33. Dammann O, Leviton A. Role of the fetus in perinatal infection and neonatal brain damage. Curr Opin Pediatr. 2000;12:99-104.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
34. Eschenbach DA. Amniotic fluid infection and cerebral palsy: focus on the fetus. JAMA. 1997;278:247-248.
FREE FULL TEXT
35. Yoon BH, Romero R, Park JS, et al. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol. 2000;182:675-681.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
36. Jeohn G-H, Kong L-Y, Wilson B, Hudson P, Hong J-S. Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron/glia cultures. J Neuroimmunol. 1998;85:1-10.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
37. Dommergues MA, Patkai J, Renauld JC, Evrard P, Gressens P. Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium. Ann Neurol. 2000;47:54-63.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
38. Deguchi K, Mizuguchi M, Takashima S. Immunohistochemical expression of tumor necrosis factor  in neonatal leukomalacia. Pediatr Neurol. 1996;14:13-16.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
39. Leviton A, Dammann O. Brain damage markers in children: neurobiological and clinical aspects. Acta Paediatr. 2002;91:9-13.
WEB OF SCIENCE
| PUBMED
40. Leviton A, Dammann O, O’Shea TM, Paneth N. Adult stroke and perinatal brain damage: like grandparent, like grandchild? Neuropediatrics. 2002;33:281-287.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
41. Dammann O, Leviton A. Brain damage in preterm newborns: biological response modification as a strategy to reduce disabilities. J Pediatr. 2000;136:433-438.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
42. Fanaroff AA, Hack M. Periventricular leukomalacia: prospects for prevention. N Engl J Med. 1999;341:1229-1231.
FREE FULL TEXT
43. Boylan GB, Young K, Panerai RB, Rennie JM, Evans DH. Dynamic cerebral autoregulation in sick newborn infants. Pediatr Res. 2000;48:12-17.
WEB OF SCIENCE
| PUBMED
44. Volpe JJ. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr Res. 2001;50:553-562.
WEB OF SCIENCE
| PUBMED
45. Volpe JJ. Cerebral white matter injury of the premature infant—more common than you think. Pediatrics. 2003;112:176-180.
FREE FULL TEXT
46. Back SA, Han BH, Luo NL, et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci. 2002;22:455-463.
FREE FULL TEXT
47. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Ann N Y Acad Sci. 1999;884:99-109.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
48. Tang HY, Hutcheson E, Neill S, Drummond-Borg M, Speer M, Alford RL. Genetic susceptibility to aminoglycoside ototoxicity: how many are at risk. Genet Med. 2002;4:336-345.
WEB OF SCIENCE
| PUBMED
49. Hack M, Breslau N, Fanaroff AA. Differential effects of intrauterine and postnatal brain growth failure in infants of very low birth weight. AJDC. 1989;143:63-68.
FREE FULL TEXT
50. Hack M, Breslau N, Weissman B, Aram D, Klein N, Borawski E. Effect of very low birth weight and subnormal head size on cognitive abilities at school age. N Engl J Med. 1991;325:231-237.
ABSTRACT
51. Dusick AM, Poindexter BB, Ehrenkranz RA, Lemons JA. Growth failure in the preterm infant: can we catch up? Semin Perinatol. 2003;27:302-310.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
52. Dusick A, Vohr BR, Steichen J, et al. Factors affecting growth outcome at 18 months in extremely low birthweight (ELBW) infants. Pediatr Res. 1998;43:213A.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Neurodevelopmental Impairment and Neonatal Infections
William Tarnow-Mordi, David Isaacs, David Henderson Smart, Ben Stenson, and Khalid Haque
JAMA. 2005;293(8):932.
EXTRACT
| FULL TEXT
Neurodevelopmental Impairment and Neonatal Infections—Reply
Barbara J. Stoll, Nellie Hansen, and for the National Institute of Child Health and Human Development Neonatal Research Network
JAMA. 2005;293(8):932.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Developmental Vulnerability and Resilience in Extremely Preterm Infants
Michael E. Msall
JAMA. 2004;292(19):2399-2401.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The use of fluconazole in neonatal intensive care units
Manzoni et al.
Arch. Dis. Child. 2009;94:983-987.
ABSTRACT
| FULL TEXT
Bovine Lactoferrin Supplementation for Prevention of Late-Onset Sepsis in Very Low-Birth-Weight Neonates: A Randomized Trial
Manzoni et al.
JAMA 2009;302:1421-1428.
ABSTRACT
| FULL TEXT
Lactoferrin Supplementation to Prevent Nosocomial Infections in Preterm Infants
Kaufman
JAMA 2009;302:1467-1468.
FULL TEXT
Fetal Inflammatory Response and Brain Injury in the Preterm Newborn
Malaeb and Dammann
J Child Neurol 2009;24:1119-1126.
ABSTRACT
Chronic Lung Disease and Developmental Delay at 2 Years of Age in Children Born Before 28 Weeks' Gestation
Laughon et al.
Pediatrics 2009;124:637-648.
ABSTRACT
| FULL TEXT
Unimpaired Outcomes for Extremely Low Birth Weight Infants at 18 to 22 Months
Gargus et al.
Pediatrics 2009;124:112-121.
ABSTRACT
| FULL TEXT
Endotoxin has acute and chronic effects on the cerebral circulation of fetal sheep
Feng et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009;296:R640-R650.
ABSTRACT
| FULL TEXT
Using a Count of Neonatal Morbidities to Predict Poor Outcome in Extremely Low Birth Weight Infants: Added Role of Neonatal Infection
Bassler et al.
Pediatrics 2009;123:313-318.
ABSTRACT
| FULL TEXT
Intrauterine, Early Neonatal, and Postdischarge Growth and Neurodevelopmental Outcome at 5.4 Years in Extremely Preterm Infants After Intensive Neonatal Nutritional Support
Franz et al.
Pediatrics 2009;123:e101-e109.
ABSTRACT
| FULL TEXT
A case definition for national and international neonatal bloodstream infection surveillance
Modi et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2009;94:F8-F12.
ABSTRACT
| FULL TEXT
Fungal Prophylaxis in the Neonatal Intensive Care Unit
Healy
NeoReviews 2008;9:e562-e570.
ABSTRACT
| FULL TEXT
Fluconazole Prophylaxis Decreases the Combined Outcome of Invasive Candida Infections or Mortality in Preterm Infants
Kaufman
Pediatrics 2008;122:1158-1159.
FULL TEXT
Bacterial colonisation of previously prepared neonatal endotracheal tubes in the delivery room
Walsh et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2008;93:F475-F476.
FULL TEXT
Human recombinant lactoferrin acts synergistically with antimicrobials commonly used in neonatal practice against coagulase-negative staphylococci and Candida albicans causing neonatal sepsis
Venkatesh and Rong
J Med Microbiol 2008;57:1113-1121.
ABSTRACT
| FULL TEXT
Morphine analgesia and gastrointestinal morbidity in preterm infants: secondary results from the NEOPAIN trial
Menon et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2008;93:F362-F367.
ABSTRACT
| FULL TEXT
Recurrent Postnatal Infections Are Associated With Progressive White Matter Injury in Premature Infants
Glass et al.
Pediatrics 2008;122:299-305.
ABSTRACT
| FULL TEXT
Behaviour difficulties and cognitive function in children born very prematurely
Bayless et al.
International Journal of Behavioral Development 2008;32:199-206.
ABSTRACT
Neurodevelopmental Outcome of Extremely Low Birth Weight Infants With Posthemorrhagic Hydrocephalus Requiring Shunt Insertion
Adams-Chapman et al.
Pediatrics 2008;121:e1167-e1177.
ABSTRACT
| FULL TEXT
Management and Outcomes of Very Low Birth Weight
Eichenwald and Stark
NEJM 2008;358:1700-1711.
FULL TEXT
Effect of long-chain polyunsaturated fatty acid supplementation of preterm infants on disease risk and neurodevelopment: a systematic review of randomized controlled trials
Smithers et al.
Am. J. Clin. Nutr. 2008;87:912-920.
ABSTRACT
| FULL TEXT
Fluconazole Prophylaxis in Extremely Low Birth Weight Neonates Reduces Invasive Candidiasis Mortality Rates Without Emergence of Fluconazole-Resistant Candida Species
Healy et al.
Pediatrics 2008;121:703-710.
ABSTRACT
| FULL TEXT
Pathogenesis of cerebral white matter injury of prematurity
Khwaja and Volpe
Arch. Dis. Child. Fetal Neonatal Ed. 2008;93:F153-F161.
ABSTRACT
| FULL TEXT
Hematologic Profile of Sepsis in Neonates: Neutrophil CD64 as a Diagnostic Marker
Bhandari et al.
Pediatrics 2008;121:129-134.
ABSTRACT
| FULL TEXT
Twelve-Month Neurofunctional Assessment and Cognitive Performance at 36 Months of Age in Extremely Low Birth Weight Infants
Gianni et al.
Pediatrics 2007;120:1012-1019.
ABSTRACT
| FULL TEXT
A Multicenter, Randomized Trial of Prophylactic Fluconazole in Preterm Neonates
Manzoni et al.
NEJM 2007;356:2483-2495.
ABSTRACT
| FULL TEXT
Neurodevelopmental Outcomes of Very Low-Birth-Weight Infants With Necrotizing Enterocolitis: A Systematic Review of Observational Studies
Schulzke et al.
Arch Pediatr Adolesc Med 2007;161:583-590.
ABSTRACT
| FULL TEXT
Neurodevelopmental and Growth Outcomes of Extremely Low Birth Weight Infants Who Are Transferred From Neonatal Intensive Care Units to Level I or II Nurseries
Lainwala et al.
Pediatrics 2007;119:e1079-e1087.
ABSTRACT
| FULL TEXT
Neurodevelopmental outcomes of neonates with medically and surgically treated necrotizing enterocolitis
Rees et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2007;92:F193-F198.
ABSTRACT
| FULL TEXT
Neonatal Coinfection Model of Coagulase-Negative Staphylococcus (Staphylococcus epidermidis) and Candida albicans: Fluconazole Prophylaxis Enhances Survival and Growth
Venkatesh et al.
Antimicrob. Agents Chemother. 2007;51:1240-1245.
ABSTRACT
| FULL TEXT
Improved Neurodevelopmental Outcomes for Extremely Low Birth Weight Infants in 2000-2002
Wilson-Costello et al.
Pediatrics 2007;119:37-45.
ABSTRACT
| FULL TEXT
Risk Factors for Seizures in Very Low Birthweight Infants With Periventricular Leukomalacia
Kohelet et al.
J Child Neurol 2006;21:965-970.
ABSTRACT
Advances in Understanding Cerebral Palsy Syndromes After Prematurity
Romantseva and Msall
NeoReviews 2006;7:e575-e585.
FULL TEXT
Impact of Prenatal and/or Postnatal Growth Problems in Low Birth Weight Preterm Infants on School-Age Outcomes: An 8-Year Longitudinal Evaluation
Casey et al.
Pediatrics 2006;118:1078-1086.
ABSTRACT
| FULL TEXT
The Association of Third-Generation Cephalosporin Use and Invasive Candidiasis in Extremely Low Birth-Weight Infants
Cotten et al.
Pediatrics 2006;118:717-722.
ABSTRACT
| FULL TEXT
Early Prediction of Sepsis-Induced Disseminated Intravascular Coagulation with Interleukin-10, Interleukin-6, and RANTES in Preterm Infants
Ng et al.
Clin. Chem. 2006;52:1181-1189.
ABSTRACT
| FULL TEXT
Laparotomy versus peritoneal drainage for necrotizing enterocolitis and perforation.
Moss et al.
NEJM 2006;354:2225-2234.
ABSTRACT
| FULL TEXT
Changing Incidence of Candida Bloodstream Infections Among NICU Patients in the United States: 1995-2004
Fridkin et al.
Pediatrics 2006;117:1680-1687.
ABSTRACT
| FULL TEXT
Neonatal Meningitis: What Is the Correlation Among Cerebrospinal Fluid Cultures, Blood Cultures, and Cerebrospinal Fluid Parameters?
Garges et al.
Pediatrics 2006;117:1094-1100.
ABSTRACT
| FULL TEXT
Delayed Cord Clamping in Very Preterm Infants Reduces the Incidence of Intraventricular Hemorrhage and Late-Onset Sepsis: A Randomized, Controlled Trial
Mercer et al.
Pediatrics 2006;117:1235-1242.
ABSTRACT
| FULL TEXT
Growth in the Neonatal Intensive Care Unit Influences Neurodevelopmental and Growth Outcomes of Extremely Low Birth Weight Infants
Ehrenkranz et al.
Pediatrics 2006;117:1253-1261.
ABSTRACT
| FULL TEXT
Fluconazole for the Prevention of Fungal Infections: Get Ready, Get Set, Caution
Fanaroff
Pediatrics 2006;117:214-215.
FULL TEXT
Multicenter Study To Determine Antibody Concentrations and Assess the Safety of Administration of INH-A21, a Donor-Selected Human Staphylococcal Immune Globulin, in Low-Birth-Weight Infants
Capparelli et al.
Antimicrob. Agents Chemother. 2005;49:4121-4127.
ABSTRACT
| FULL TEXT
Seventy-Five Years of Neonatal Sepsis at Yale: 1928-2003
Bizzarro et al.
Pediatrics 2005;116:595-602.
ABSTRACT
| FULL TEXT
Rapid Feeding Volume Advancements: Uncertainty About the Effect on Necrotizing Enterocolitis Incidence
Degraeuwe and Blanco
Pediatrics 2005;115:1439-1439.
FULL TEXT
Rapid Feeding Volume Advancements: Uncertainty About the Effect on Necrotizing Enterocolitis Incidence: In Reply
Caple et al.
Pediatrics 2005;115:1439-1439.
FULL TEXT
Neurodevelopmental Impairment and Neonatal Infections
Tarnow-Mordi et al.
JAMA 2005;293:932-932.
FULL TEXT
Neurodevelopmental Aftereffects of Neonatal Infections
JWatch Infect. Diseases 2004;2004:7-7.
FULL TEXT
Developmental Vulnerability and Resilience in Extremely Preterm Infants
Msall
JAMA 2004;292:2399-2401.
FULL TEXT
|
